Advertisement
Canada markets open in 5 hours 26 minutes
  • S&P/TSX

    22,259.16
    -31.46 (-0.14%)
     
  • S&P 500

    5,187.67
    -0.03 (-0.00%)
     
  • DOW

    39,056.39
    +172.13 (+0.44%)
     
  • CAD/USD

    0.7281
    -0.0007 (-0.10%)
     
  • CRUDE OIL

    79.55
    +0.56 (+0.71%)
     
  • Bitcoin CAD

    84,142.90
    -1,212.58 (-1.42%)
     
  • CMC Crypto 200

    1,323.43
    +23.33 (+1.82%)
     
  • GOLD FUTURES

    2,316.10
    -6.20 (-0.27%)
     
  • RUSSELL 2000

    2,055.14
    -9.51 (-0.46%)
     
  • 10-Yr Bond

    4.4920
    +0.0290 (+0.65%)
     
  • NASDAQ futures

    18,130.25
    -56.25 (-0.31%)
     
  • VOLATILITY

    13.16
    +0.16 (+1.23%)
     
  • FTSE

    8,352.01
    -2.04 (-0.02%)
     
  • NIKKEI 225

    38,073.98
    -128.39 (-0.34%)
     
  • CAD/EUR

    0.6781
    +0.0005 (+0.07%)
     

Analysts Are Bullish on Sarepta Therapeutics

Analysts Are Bullish on Sarepta Therapeutics

Wall Street analysts estimate Sarepta will report a net loss of $0.89 per share on revenues of $71.6 million in Q2 2018, which is more than a 100% YoY increase in revenues as compared to $35.0 million during the second quarter of 2017. Wall Street analyst estimates suggest the stock has the potential to return ~51.4% over the next 12 months. As of August 6, 19 analysts were tracking Sarepta Therapeutics stock.